SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression In AML Xenograft Models

SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, announced as part of a series of presentations at the 2008 AACR Annual Meeting that that it has identified a lead PIM kinase inhibitor, SGI-1776, that causes tumor regression in acute myologenous leukemia (AML) xenograft models (Abstract No. 4974).

More: continued here

Filed under: Clinical Trials on April 17th, 2008